Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOG mRNA Tol-cLNP vaccine
- Development stage
- Preclinical
- Lead developer
- etherna
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Intravenous
01
Overview
MOG mRNA Tol-cLNP vaccine is an investigational tolerizing mRNA-lipid nanoparticle (LNP) vaccine developed by etherna in collaboration with Hasselt University for the treatment of multiple sclerosis (MS). The vaccine consists of mRNA encoding myelin oligodendrocyte glycoprotein (MOG) (specifically MOG27-63) encapsulated in customized tolerizing lipid nanoparticles (Tol-cLNP). It is designed to target antigen-presenting cells (APCs) in the liver and spleen to present the MOG antigen in an immune-silent manner. This induces antigen-specific tolerance by promoting a homeostatic APC phenotype and driving the proliferation of MOG-specific T cells into an exhausted, anti-inflammatory phenotype with increased IL-10 expression, thereby suppressing autoimmune responses without causing generalized immunosuppression.
- Other names
- MOG mRNA Tol-cLNPMOG mRNA-loaded Tol-cLNPMOG mRNA-loaded tolerizing lipid nanoparticlesMOG27-63 mRNA-loaded LNPsMOG-27-63 mRNA-loaded LNPsMOG 27-63 mRNA-loaded LNPs
Beyond the preview
Go deeper on MOG mRNA Tol-cLNP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MOG mRNA Tol-cLNP vaccine.